RAB27B expression in pancreatic cancer is predictive of poor survival but good response to chemotherapy

Abstract

BACKGROUND:

Pancreatic cancer is the 4th leading cause of cancer-related death with poor survival even after curative resection. RAB27A and RAB27B are key players in the exosome pathway where they play important roles in exosome secretion. Evidence suggests that RAB27A and RAB27B expression not only leads to tumor proliferation and invasion, but also plays an important role in antigen transfer necessary for anticancer immunity.

OBJECTIVE:

In this study, we analyze the expression of RAB27A and RAB27B in patients after pancreatic cancer surgery with or without adjuvant chemotherapy and its influence on overall survival.

METHODS:

We analyzed a total of 167 patients with pancreatic cancer for their RAB27A and RAB27B expression. We dichotomized the patients along the median and compared survival in patients with high and low RAB27A and RAB27B expression with or without adjuvant chemotherapy treatment.

RESULTS:

We found a significant improvement in overall survival in patients with a negative resection margin ( $p=$ 0.037) and in patients who received adjuvant chemotherapy ( $p=$ 0.039). The survival benefit after chemotherapy was dependent on RAB27B expression status: only the subgroup of patients with high RAB27B expression benefited from adjuvant chemotherapy ( $p=$ 0.006), but not the subgroup with low RAB27B expression ( $p=$ 0.59). Patients with high RAB27B expression who did not receive adjuvant chemotherapy showed a trend towards worse survival compared to the other subgroups. This difference was abolished after treatment with adjuvant chemotherapy.

CONCLUSION:

These results suggest that RAB27B expression in pancreatic cancer might identify a subgroup of patients with poor survival who might respond well to adjuvant chemotherapy. If resectable, these patients could be considered for neoadjuvant chemotherapy to minimize the risk of not receiving adjuvant chemotherapy. Further prospective studies are needed to confirm these findings.

Keywords

Exosomes RAB27B pancreatic cancer chemotherapy treatment response

1. Introduction

Pancreatic cancer is the fourth most common cause of cancer-related death in developed countries with a 5-year overall survival (OS) of only 10% [1, 2]. Only 15–20% of patients are eligible for surgery, with a dismal 20% 5-year OS after curative resection [3]. The projected doubling of pancreatic cancer incidence by 2030 would make it the second leading cause of cancer-related deaths after lung cancer [4]. The poor survival of pancreatic cancer is due to late clinical presentation due to asymptomatic early disease and the aggressive biology combined with a dense, fibroblast rich tumor microenvironment leading to early metastasis and resistance to chemotherapy [5].

New methods to identify cancer-specific exosomes have shown excellent early detection of pancreatic cancer under study conditions but are still far from clinical translation [6]. Exosomes are small membrane vesicles with a size of 50–100 nm that play a role in intercellular communication by exchanging microRNA, mRNA, DNA fragments and proteins between the different tumor compartments [7].

At the core of exosome regulation are small GTPases belonging to the RAB family: RAB27A and RAB27B. Both have been shown to control important functions in the exosome pathway, particularly vesicle trafficking. RAB27A and RAB27B can switch between their active GTP-bound and inactive GDP-bound forms, acting as switches to regulate vesicle trafficking [8]. Silencing of the RAB27 effectors Slp4 and Slac2b significantly reduces exosome expression [9]. Several studies have shown that RAB27A and RAB27B control exosome secretion in several cancer cell types, including breast cancer, melanoma, bladder cancer, lung cancer and cervical cancer [10, 11, 12, 13, 14, 15]. Furthermore, in vitro studies in pancreatic cancer cell lines have shown that RAB27A and RAB27B expression in cancer cells increases proliferation and invasion, decreases apoptosis and leads to resistance to cisplatin therapy [16]. Accordingly, high RAB27A and RAB27B expression has been described as a marker of poor prognosis in several cancers, including pancreatic cancer [17, 18, 19, 20]. However, the existing literature in pancreatic cancer is based on a single cohort of patients without information on response to chemotherapy.

Exosomes play an essential role in intercellular communication, such as the interaction between tumor cells and the immune system. The regulation of the immune system by exosomes is a relatively new area of research. Exosomes have been shown to influence antigen presentation, immune activation, and immunosuppression [21]. Tumor exosomes are a source of tumor antigens that can be used to cross-activate cytotoxic T-cells [22]. Conversely, Rab27B knockout mice showed an impaired immune system with a weak response to bacterial LPS [23].

Finally, the response to chemotherapy is strongly influenced by the immune system, either by activating immune cells through antigen release from dying cancer cells, or by mediating off-target effects on immune cell populations [24, 25, 26, 27]. Conversely, chemotherapy can also improve the outcome of immunotherapy [28, 29]. In summary, exosomes play a plethora of complex roles in cancer growth, metastasis and immunomodulation, as well as some basic immunological roles such as antigen presentation and antitumor immunity.

In this study, we will shed some light on the clinical relevance of exosomes by investigating the clinical relevance of RAB27A and RAB27B on OS in the context of chemotherapy response in pancreatic cancer.

2. Material and methods

2.1 Patients samples and tissue collection

This study was conducted in accordance with the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) [30]. This study was designed as an exploratory study. All patients gave their informed consent prior to resection and the study was approved by the Ethics Committee of the Technical University of Dresden (EK 59032007).

A total of 245 patients, who underwent curative resection for histologically proven ductal adenocarcinoma of the pancreas, were screened. 33 patients were excluded due to missing survival data ( $n=$ 5) or missing tumor samples ( $n=$ 28), leaving 212 patients in the study. An additional 45 patients were excluded for failure to meet the inclusion criteria (the presence of two stained tumor samples including exocrine pancreatic ducts), leaving 167 patients for final analysis (160 patients for RAB27B and 146 patients for RAB27A analysis; Fig. 1).

Figure 1.

Flowchart of patient inclusion.

The tissue was studied in the form of tissue microarrays with individual tissue samples of 0.6 mm diameter. The microarray contained two samples from the same patient to reduce the risk of bias. Only patients with at least two separate tumor samples with pancreatic ducts were included in the final analysis. The tissue microarray was prepared by the Pathology Department of the University Hospital in Dresden, Germany. The histological evaluation of the samples was performed in a blinded fashion and the unblinding of the clinical data was performed after completion of the histological staining and evaluation.

2.2 Tissue microarray and immunohistochemistry

Tissue microarrays (TMAs) were prepared by the Pathology Department of the University Hospital Dresden using a manual tissue microarray system (MTA-1 from Beecher). All samples were fixed in formaldehyde, punched in duplicates of 0.6 mm diameter and embedded in paraffin. Tissues from different organs were included in each TMA for reference. Hematoxylin-eosin staining was performed to assess both the presence of tumor tissue in the samples and the overall quality of the TMA.

Sections of 2 $\mu$ m thickness were dried at 70 ${}^{\circ}$ C. Immunohistochemistry (IHC) was performed using a mouse monoclonal anti-human RAB27A antibody (Santa Cruz 74586; 1:500) and a rabbit polyclonal anti-human RAB27B antibody (HPA019849; Sigma-Aldrich; 1:450) [31]. Both antibodies were previously tested and validated by the Human Protein Atlas Project (www.proteinatlas.org). IHC was performed using an automated IHC staining system (BenchMark CT, Roche) and the appropriate staining kit (OptiView DAB IHC Detection Kit; Ventana Inc.) to ensure optimal reproducibility.

2.3 Immunohistochemistry evaluation

Stained slides were scanned and evaluated using the Ventana Image Viewer (version 3.1.0.0; Ventana Medical System). H-scores were calculated using the following formula: [(0 x % negative cells) $+$ (1 x % weakly positive cells) $+$ (2 x % moderately positive cells) $+$ (3 x % strongly positive cells)]. The H-score is a semiquantitative score including signal intensity and percentage of stained cells with a possible range of 0–300 [32] (Fig. 2).

Figure 2.

Examples of staining intensities (SI) in the tissue microarray (TMA).

Table 1

Clinical characteristics broken down by high or low RAB27A and RAB27B expression

Clinical data
	RAB27B low ( $<$ 95)		RAB27B high ( $>=$ 95)		RAB27A low ( $<$ 35)		RAB27A high ( $>=$ 35)
	$N=$ 81		$N=$ 79		$N=$ 75		$N=$ 71
AGE (mean, min-max)	66	(40–84)	65	(40–81)	65	(40–84)	66	(40–84)
SEX
Male	43	(53%)	45	(57%)	42	(56%)	39	(55%)
Female	38	(47%)	33	(42%)	33	(44%)	32	(45%)
Missing			1	(1%)
Tumor stage
T1	0	(0%)	0	(0%)	0	(0%)	0	(0%)
T2	6	(7%)	5	(6%)	4	(5%)	4	(6%)
T3	75	(93%)	73	(92%)	71	(95%)	67	(94%)
T4	0	(0%)	1	(1%)	0	(0%)	0	(0%)
Lymph node stage
N0	28	(35%)	24	(30%)	22	(29%)	21	(30%)
N1	51	(63%	54	(68%)	52	(69%)	49	(69%)
N2	2	(3%)	1	(1%)	1	(1%)	1	(1%)
Metastases
M0	70	(86%)	71	(90%)	68	(91%)	64	(90%)
M1	6	(7%)	2	(3%)	2	(3%)	2	(3%)
Mx	5	(6%)	6	(8%)	5	(7%)	5	(7%)
Grading
G1	1	(1%)	1	(1%)	1	(1%)	1	(1%)
G2	37	(46%)	46	(58%)	36	(48%)	34	(48%)
G3	42	(52%)	30	(38%)	37	(49%)	35	(49%)
Gx	1	(1%)	2	(3%)	1	(1%)	1	(1%)
Resection
R0	50	(62%)	48	(61%)	45	(60%)	41	(58%)
R1	19	(24%)	26	(33%)	21	(28%)	21	(30%)
R2	8	(10%)	2	(3%)	7	(9%)	7	(10%)
Rx	4	(5%)	3	(4%)	2	(3%)	2	(3%)
Adjuvant therapy
Yes	37	(46%)	42	(53%)	30	(40%)	28	(39%)
No	44	(54%)	37	(47%)	45	(60%)	43	(60%)

2.4 Statistical analysis

For statistical analysis, the H-values for RAB27A and RAB27B were dichotomized along the median and along the previously described cutoff values for reference [33]. Statistical analysis was performed with SPSS version 28 (SPSS 28.0.1.0, IBM). Survival statistics were performed using Kaplan-Meier curves and the log-rank test. Hazard ratios, 95% confidence intervals (CI), and the corresponding $p$ -values were calculated using the Cox-regression model.

3. Results

3.1 Patient characteristics

The tissue for the tissue microarray was collected consecutively at the University Hospital Dresden between 1998 and 2011. The mean age was 66 years (40–84), 73 patients (44%) were female and 93 (56%) were male, T stage was T2 in 13 patients (8%), T3 in 153 patients (92%) and T4 in 1 patient (1%), lymph node status was N0 in 55 patients (33%), N1 in 109 (65%) and N2 in 3 (2%) patients, Metastatic status was M0 (no metastases) in 147 patients (88%), M1 (distant metastases) in 8 (5%), and Mx (missing information) in 12 (7%) of the patients, the tumor grading was G1 in 2 (1%), G2 in 83 (50%), G3 in 79 (48%), and missing in 3 (2%) of the patients. Follow-up was complete in 88%, with a median follow-up of 67 months for the remaining patients.

100 (69%) patients had a R0 status, 47 (28%) patients had a R1 status and 12 (7%) patients had a R2 status postoperatively. 84 (50%) of the patients received adjuvant chemotherapy and 83 (50%) did not. Detailed results are shown in Table 1.

Table 2
Hazard ratios of clinical factors as well as RAB27B expression for overall survival. RAB27B was dichotomized along the median (RAB27B $\leqslant$ 95) and along previously described cutoff values (RAB27B $\leqslant$ 90) [15, 16]

Overall survival
Including all 167 patients
	$n=$ 167	HR	95% CI	$p$ -value
AGE
$>$ 65 vs $\leqslant$ 65	97/68	1.17	0.84–1.63	0.36
Missing	2
SEX
Female vs. male	73/93	1.07	0.77–1.49	0.68
Missing	1
T-stage
3–4 vs. 1–2	154/13	1.085	0.60–1.96	0.79
Lymph node stage
N pos vs. neg	112/55	1.3	0.91–1.85	0.14
UICC stage
Stage 2B-4 vs. 1-2A	113/54	1.33	0.93–1.89	0.11
Metastases
M pos vs. neg	8/147	0.97	0.48–1.99	0.94
Grading
G3–4 vs G1–2	79/85	1.23	0.89–1.71	0.21
Missing	3
Resection
R pos vs. neg	59/100	1.44	1.02–2.03	0.037
Missing	8
Adjuvant therapy
Yes vs no	84/83	0.71	0.51–0.98	0.039
RAB27A
High vs. low (med $\leqslant$ 35)	75/74	1.01	0.73–1.41	0.94
High vs. low ( $\leqslant$ 90)	11/138	1.13	0.61–2.09	0.7
RAB27B
High vs. low (med $\leqslant$ 95)	79/81	1.08	0.76–1.52	0.68
High vs. low ( $\leqslant$ 90)	83/77	1.11	0.79–1.54	0.56

3.2 Correlation of clinical factors with overall survival

The influence of the different clinical factors on OS was investigated using the Cox regression model. While age, sex and tumor grade did not show a significant correlation with OS, positive lymph node involvement and higher UICC status both showed a trend towards worse survival (N $+$ : HR 1.3 95% CI 0.91–1.85, $p=$ 0.14; UICC $\geqslant$ 2B: HR 1.33 95% CI 0.93–1.89, $p=$ 0.11). Tumor stage and metastatic disease could not be properly assessed due to the very small number of patients with early T1 or T2 disease and very few patients with metastatic disease. Positive resection margins (HR 1.44, 95% CI 1.02–2.03, $p=$ 0.04) and the administration of adjuvant chemotherapy (HR 0.71, 95% CI 0.51–0.98, $p=$ 0.04) had a significant impact on OS. These results correlated well with previous publications (Table 2).

3.3 Correlation of RAB27A and RAB27B expression with overall survival

To evaluate the RAB27A and RAB27B expression and its impact on OS, H-scores were dichotomized using previously described cutoff values for H-scores in pancreatic cancer [33, 34] and the median of the patient cohort. The cox regression model was used to evaluate any potential impact on survival. Surprisingly, neither RAB27A nor RAB27B expression was significantly associated with OS. These results remained unchanged whether the median or the previously described cutoff values were used (Table 2).

3.4 Correlation of clinical factors within the subgroups of patients with high or low RAB27A and RAB27B expression

To evaluate the influence of RAB27A and RAB27B expression on chemotherapy response, we created subgroups of patients with high and low RAB27A and RAB27B expression, respectively. The clinical factors in the high and low RAB27A and RAB27B expression groups were relatively homogeneous. The group of patients with high RAB27B expression had slightly more low grade cancers (G1/G2) than the patients with low RAB27B expression (Table 3).

Table 3
Evaluation of RAB27B expression as a predictor for poor survival. Patients with high RAB27B expression are shown on the right, patients with low RAB27B expression are shown on the left. Hazard Ratios (HR), 95% confidence intervals (95% CI) and $p$ -values ( $p$ ) were calculated using a Cox regression

	RAB27B low ( $\leqslant$ 95)				RAB27B high ( $>$ 95)
	$N=$ 81	HR	95% CI	$p$	$n=$ 79	HR	95% CI	$p$
AGE
$>$ 65 vs $\leqslant$ 65	46/33	1.25	0.77–2.03	0.35	48/30	1.06	0.65–1.72	0.82
SEX
F vs. M	38/43	0.86	0.54–1.38	0.54	33/45	1.39	0.86–2.23	0.18
T3–4 vs T1–2	75/6	1.39	0.56–3.46	0.48	74/5	0.68	0.27–1.71	0.41
N pos vs. neg	53/28	1.46	0.87–2.43	0.15	55/24	1.08	0.65–1.81	0.77
M pos vs. neg	6/70	1.27	0.55–2.96	0.57	2/71	0.57	0.14–2.33	0.43
G3–4 vs G1–2	42/38	0.98	0.64–1.57	0.94	30/47	1.66	1.00–2.76	0.05
R pos vs. neg	27/50	1.72	1.04–2.85	0.04	28/48	1.11	0.67–1.83	0.69
Adjuvant
Yes vs no	37/44	0.88	0.55–1.41	0.59	42/37	0.52	0.32–0.84	0.007

Figure 3.

Kaplan Meier curves of patients with or without adjuvant chemotherapy that did and did not receive chemotherapy for A) all patients B) patients with low RAB27B expression and C) patients with high RAB27B expression. $P$ -values were calculated using the log rank test.

While there was no significant correlation with OS in both RAB27A subgroups (Supplementary Table 1), the RAB27B subgroups showed significant differences.

In the subgroup of patients with high RAB27B expression, significantly worse OS was observed in patients with higher tumor grade (HR 1.66, 95% CI 1.00–2.76, $p=$ 0.05) and significantly better survival in patients who received adjuvant chemotherapy (HR 0.52; 95% CI 0.32–0.84; $p=$ 0.007). In contrast, patients with low RAB27B expression showed no significant change in OS with respect to tumor grading (HR 0.98; 95% CI 0.64–1.57; $p=$ 0.94) or adjuvant chemotherapy (HR 0.88; 95% CI 0.55–1.41; $p=$ 0.59). On the other hand, the subgroup with low RAB27B expression showed a significant correlation between resection status and OS (HR 1.72; 95% CI 1.04–2.85; $p=$ 0.04).

We then compared the grading in the patients with high RAB27B expression and found no difference in the distribution of patients receiving (G1/2 vs. G3/4: 25/18) and not receiving (G1/2 vs. G3/4: 22/14) adjuvant chemotherapy. Thus, we can safely exclude an allocation bias.

These results suggest that patients with high RAB27B expression are more sensitive to adjuvant chemotherapy. In contrast, patients with low RAB27B expression do not appear to respond to adjuvant chemotherapy.

Finally, we compared survival in the 4 subgroups, patients with low RAB27B expression without adjuvant chemotherapy, patients with low RAB27B expression who received adjuvant chemotherapy, patients with high RAB27B expression without adjuvant chemotherapy, and patients with high RAB27B expression who received adjuvant chemotherapy.

As discussed above, patients with low RAB27B expression did not show a survival difference between patients with or without adjuvant chemotherapy. However, patients with high RAB27B expression without adjuvant chemotherapy had significantly worse survival compared to patients who received adjuvant chemotherapy ( $p=$ 0.006). Patients with high RAB27B expression without adjuvant chemotherapy showed a trend towards worse survival compared to patients with low RAB27B expression ( $p=$ 0.09), while patients with high RAB27B expression who received adjuvant chemotherapy showed no difference in OS (Fig. 3 and Supplementary Fig. 1).

These data suggest that RAB27B is indeed a predictor of poor survival as well as a predictor of chemosensitivity.

4. Limitations of this study

The included patients were resected between 1998 and 2011, none of them received neoadjuvant chemotherapy, and almost all of them received gemcitabine as adjuvant chemotherapy. The FOLFIRINOX chemotherapy regimen consisting of oxaliplatin, fluorouracil, leucovorin and irinotecan was first described in 2011 [35], while the gemcitabine/nab-paclitaxel combination was introduced in 2013 [36]. At the same time, an increasing number of elderly patients are being diagnosed with pancreatic cancer and are still receiving gemcitabine therapy due to frailty or poor ECOG status. In addition, while newer therapies are more aggressive, they also rely on the immune system for their effect [37].

5. Discussion

Exosomes are a new player in intercellular communication that have been shown to influence tumor growth, metastasis and the antitumoral immune response [7]. Two small GTPases, RAB27A and RAB27B, are at the core of exosome regulation. Both have been shown to control important functions in the exosome pathway, particularly in vesicle trafficking. Silencing of RAB27A and/or RAB27B results in a significant decrease in exosome expression [9]. Several publications have examined the impact of RAB27B expression on survival in various cancers. However, this is the first publication to show that RAB27B is not only a prognostic marker for poor survival in pancreatic cancer, but also a predictor of response to chemotherapy.

The literature is divided on the role of RAB27B expression in cancer. While some studies show poor survival in cancers that overexpress RAB27B [17, 38], other studies show the opposite [39, 40]. These different results could be explained by the conflicting roles that exosomes play in the crosstalk between cancer cells and the immune system.

On the one hand, recent studies have shown that exosome transfer of the EGFR-19del to the dendritic cell (DC) surface leads to impaired DC function in EGFR-19del-expressing Lewis lung cancer tumors [41]. Furthermore, exosomal PD-L1 secretion from cancer cells is part of their immune-evasion strategy [42] and could induce resistance to immunotherapy by inhibiting cytotoxic T-cells in draining lymph nodes [43].

On the other hand, exosomes are required for the transfer of tumor cell antigens to dendritic cells, thereby initiating the antitumor cytotoxic T-cell response [44]. Tumor exosomes are a source of tumor antigens that can be used to cross-activate cytotoxic T cells [22]. A knockout model of Rab27B mice showed an impaired immune system with a weak response to bacterial LPS [23].

In conclusion, although exosomes can lead to therapy resistance, they are required for the antitumor immune response.

In this study, we could show that pancreatic cancers with high RAB27B expression tend to be more aggressive with poorer overall survival compared to patients with low RAB27B expression. At the same time, these cancers respond significantly better to chemotherapy, with no difference in survival between patients with high and low RAB27B expression who both received chemotherapy. This may be due to a more effective immune response following chemotherapy-induced cancer cell death.

The expression of RAB27B in tumors may therefore be useful in identifying patients who may benefit from chemotherapy. Major postoperative complications or general morbidity after surgery may prevent the administration of adjuvant chemotherapy. This is one of the reasons why neoadjuvant chemotherapy is being considered to be extended from borderline resectable pancreatic cancer patients to resectable patients. Only about 50–60% of patients receive adjuvant chemotherapy after resection for pancreatic cancer [45]. Conversely, side effects after neoadjuvant chemotherapy may prevent curative surgery [46]. RAB27B expression may help to identify patients who may benefit from neoadjuvant chemotherapy.

6. Conclusion

We conclude that RAB27B is a potential prognostic marker for response to chemotherapy in pancreatic cancer. High RAB27B expression may identify patients who may benefit from neoadjuvant chemotherapy. Further studies as well as prospective studies are needed to confirm these findings.

Author contributions

Conception: Mathieu Pecqueux.

Interpretation or analysis of data: Mathieu Pecqueux, Beate Wende, Sebastian Hempel, Florian Oehme, Ulrich Sommer, Daniela Aust, Franziska Baenke.

Preparation of the manuscript: Mathieu Pecqueux, Christoph Kahlert, Florian Oehme, Sebastian Hempel.

Revision for important intellectual content: Franziska Baenke, Florian Oehme, Sebastian Hempel, Ulrich Sommer, Daniela Aust.

Supervision: Marius Distler, Jürgen Weitz, Christoph Kahlert.

Supplementary data

The supplementary files are available to download from https://dx-doi-org.web.bisu.edu.cn/10.3233/CBM-220460.

sj-docx-1-cbm-10.3233_CBM-220460.docx - Supplemental material

Supplemental material, sj-docx-1-cbm-10.3233_CBM-220460.docx

Footnotes

Acknowledgments

The study was fully funded by the Clinic for Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Germany. We thank Heike Polster for her assistance in the collection of clinical patient data.

References

Siegel

R.L.

Miller

K.D.

and Jemal

, Cancer statistics, 2019 (US statistics), CA Cancer J Clin 69 (2019), 7–34.

Koch-Institut

, Krebs in Deutschland für 2017/2018, 2017.

Mizrahi

J.D.

Surana

Valle

J.W.

and Shroff

R.T.

, Pancreatic cancer, The Lancet 395 (2020), 2008–2020.

Rahib

Smith

B.D.

Aizenberg

Rosenzweig

A.B.

Fleshman

J.M.

and Matrisian

L.M.

, Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states, Cancer Res 74 (2014), 2913–2921.

Lafaro

K.J.

and Melstrom

L.G.

, The paradoxical web of pancreatic cancer tumor microenvironment, American Journal of Pathology 189 (2019), 44–57.

Melo

S.A.

Luecke

L.B.

Kahlert

Fernandez

A.F.

Seth

Kaye

Lebleu

V.S.

Mittendorf

E.A.

Weitz

Reissfelder

Pilarsky

Fraga

M.F.

and Piwnica-

, Detection of Cancer, 523 (2016), 177–182.

Kahlert

and Kalluri

, Exosomes in tumor microenvironment influence cancer progression and metastasis, J Mol Med 91 (2013), 431–437.

Barr

and Lambright

D.G.

, Rab GEFs and GAPs, Curr Opin Cell Biol 22 (2010), 461–470.

Ostrowski

Carmo

N.B.

Krumeich

Fanget

Raposo

Savina

Moita

C.F.

Schauer

Hume

A.N.

Freitas

R.P.

Goud

Benaroch

Hacohen

Fukuda

Desnos

Seabra

M.C.

Darchen

Amigorena

Moita

L.F.

and Thery

, Rab27a and Rab27b control different steps of the exosome secretion pathway, Nat Cell Biol 12 (2010), 19–30.

10.

Ostrowski

Carmo

N.B.

Krumeich

Fanget

Raposo

Savina

Moita

C.F.

Schauer

Hume

A.N.

Freitas

R.P.

Goud

Benaroch

Hacohen

Fukuda

Desnos

Seabra

M.C.

Darchen

Amigorena

Moita

L.F.

and Thery

, Rab27a and Rab27b control different steps of the exosome secretion pathway, Nat Cell Biol 12 (2010), 19–30.

11.

Zheng

Campbell

E.C.

Lucocq

Riches

and Powis

S.J.

, Monitoring the Rab27 associated exosome pathway using nanoparticle tracking analysis, Exp Cell Res 319 (2013), 1706–1713.

12.

Bobrie

Krumeich

Reyal

Recchi

Moita

L.F.

Seabra

M.C.

Ostrowski

and Théry

, Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression, Cancer Res 72 (2012), 4920–4930.

13.

Ostenfeld

M.S.

Jeppesen

D.K.

Laurberg

J.R.

Boysen

A.T.

Bramsen

J.B.

Primdal-Bengtson

Hendrix

Lamy

Dagnaes-Hansen

Rasmussen

M.H.

Bui

K.H.

Fristrup

Christensen

E.I.

Nordentoft

Morth

J.P.

Jensen

J.B.

Pedersen

J.S.

Beck

Theodorescu

Borre

Howard

K.A.

Dyrskjøt

and Ørntoft

T.F.

, Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties, Cancer Res 74 (2014), 5758–5771.

14.

Jiang

Han

Chen

and Li

, Rab27A regulates exosome secretion from lung adenocarcinoma cells A549: involvement of EPI64, APMIS, 2014, n/a-n/a.

15.

Peinado

Alečković

Lavotshkin

Matei

Costa-Silva

Moreno-Bueno

Hergueta-Redondo

Williams

García-Santos

Ghajar

C.M.

Nitadori-Hoshino

Hoffman

Badal

Garcia

B.A.

Callahan

M.K.

Yuan

Martins

V.R.

Skog

Kaplan

R.N.

Brady

M.S.

Wolchok

J.D.

Chapman

P.B.

Kang

Bromberg

and Lyden

, Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET, Nat Med 18 (2012), 883–891.

16.

Jin

Huang

Tang

and Huang

, Effects of Rab27A and Rab27B on Invasion, Proliferation, Apoptosis, and Chemoresistance in Human Pancreatic Cancer Cells, Pancreas 46 (2017), 1173–1179.

17.

Zhao

Wang

Zhu

Zhang

Wang

and Huang

, Correlation Between RAB27B and p53 Expression and Overall Survival in Pancreatic Cancer, Pancreas 45 (2016), 204–210.

18.

Koh

H.M.

Jang

B.G.

and Kim

D.C.

, Prognostic significance of Rab27 expression in solid cancer: A systematic review and meta-analysis, Sci Rep 10 (2020), 14136.

19.

H.J.

Song

D.H.

Koh

H.M.

G.H.

Lee

J.-H.

Kim

D.C.

Yang

J.W.

Kim

M.H.

Seo

D.H.

Jang

S.M.

and Lee

J.S.

, RAB27A is an independent prognostic factor in clear cell renal cell carcinoma, Biomark Med 13 (2019), 239–247.

20.

Wang

Zhu

Wang

and Huang

, High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival, Medical Oncology 32 (2015), 372.

21.

Barros

F.M.

Carneiro

Machado

J.C.

and Melo

S.A.

, Exosomes and immune response in cancer: Friends or foes, Front Immunol 9 (2018).

22.

Andre

Schartz

N.E.

Movassagh

Flament

Pautier

Morice

Pomel

Lhomme

Escudier

le Chevalier

Tursz

Amigorena

Raposo

Angevin

and Zitvogel

, Malignant effusions and immunogenic tumour-derived exosomes, The Lancet 360 (2002), 295–305.

23.

Alexander

Ramstead

A.G.

Bauer

K.M.

Lee

S.-H.

Runtsch

M.C.

Wallace

Huffaker

T.B.

Larsen

D.K.

Tolmachova

Seabra

M.C.

Round

J.L.

Ward

D.M.

and O’Connell

R.M.

, Rab27-dependent exosome production inhibits chronic inflammation and enables acute responses to inflammatory stimuli, The Journal of Immunology 199 (2017), 3559–3570.

24.

Obeid

Tesniere

Ghiringhelli

Fimia

G.M.

Apetoh

Perfettini

J.L.

Castedo

Mignot

Panaretakis

Casares

Métivier

Larochette

van Endert

Ciccosanti

Piacentini

Zitvogel

and Kroemer

, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat Med 13 (2007), 54–61.

25.

Apetoh

Ghiringhelli

Tesniere

Obeid

Ortiz

Criollo

Mignot

Maiuri

M.C.

Ullrich

Saulnier

Yang

Amigorena

Ryffel

Barrat

F.J.

Saftig

Levi

Lidereau

Nogues

Mira

J.-P.

Chompret

Joulin

Clavel-Chapelon

Bourhis

André

Delaloge

Tursz

Kroemer

and Zitvogel

, Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat Med 13 (2007), 1050–1059.

26.

Ghiringhelli

Apetoh

Tesniere

Aymeric

Ortiz

Vermaelen

Panaretakis

Mignot

Ullrich

Perfettini

J.-L.

Schlemmer

Tasdemir

Uhl

Génin

Civas

Ryffel

Kanellopoulos

Tschopp

André

Lidereau

McLaughlin

N.M.

Haynes

N.M.

Smyth

M.J.

Kroemer

and Zitvogel

, Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β – dependent adaptive immunity against tumors, Nat Med 15 (2009), 1170–1178.

27.

Ciampricotti

Hau

C.-S.

Doornebal

C.W.

Jonkers

and de Visser

K.E.

, Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system, Nat Med 18 (2012), 344–346.

28.

Wei

S.C.

Duffy

C.R.

and Allison

J.P.

, Fundamental mechanisms of immune checkpoint blockade therapy, Cancer Discov 8 (2018), 1069–1086.

29.

Emens

L.A.

and Middleton

, The interplay of immunotherapy and chemotherapy: Harnessing potential synergies, Cancer Immunol Res 3 (2015), 436–443.

30.

McShane

L.M.

Altman

D.G.

Sauerbrei

Taube

S.E.

Gion

and Clark

G.M.

, REporting recommendations for tumor MARKer prognostic studies (REMARK), Nat Clin Pract Oncol 2 (2005), 416–422.

31.

Uhlén

Fagerberg

Hallström

B.M.

Lindskog

Oksvold

Mardinoglu

Sivertsson

Å.

Kampf

Sjöstedt

Asplund

Olsson

Edlund

Lundberg

Navani

Szigyarto

C.A.-K.

Odeberg

Djureinovic

Takanen

J.O.

Hober

Alm

Edqvist

P.-H.

Berling

Tegel

Mulder

Rockberg

Nilsson

Schwenk

J.M.

Hamsten

von Feilitzen

Forsberg

Persson

Johansson

Zwahlen

von Heijne

Nielsen

and Pontén

, Tissue-based map of the human proteome, Science (1979) 347 (2015).

32.

Thike

A.A.

Chng

M.J.

Tan

P.H.

and Fook-Chong

, Immunohistochemical expression of hormone receptors in invasive breast carcinoma: Correlation of results of H-score with pathological parameters, Pathology 33 (2001), 21–25.

33.

Zhao

Wang

Zhu

Zhang

Wang

and Huang

, Correlation Between RAB27B and p53 Expression and Overall Survival in Pancreatic Cancer, 45 (2016), 204–210.

34.

Wang

Zhu

Wang

and Huang

, High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival, Med Oncol 32 (2015), 372.

35.

Conroy

Desseigne

Ychou

Bouché

Guimbaud

Bécouarn

Adenis

Raoul

J.-L.

Gourgou-Bourgade

de la Fouchardière

Bennouna

Bachet

J.-B.

Khemissa-Akouz

Péré-Vergé

Delbaldo

Assenat

Chauffert

Michel

Montoto-Grillot

and Ducreux

, FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine 364 (2011), 1817–1825.

36.

von Hoff

D.D.

Ervin

Arena

F.P.

Chiorean

E.G.

Infante

Moore

Seay

Tjulandin

S.A.

W.W.

Saleh

M.N.

Harris

Reni

Dowden

Laheru

Bahary

Ramanathan

R.K.

Tabernero

Hidalgo

Goldstein

van Cutsem

Wei

Iglesias

and Renschler

M.F.

, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, New England Journal of Medicine 369 (2013), 1691–1703.

37.

Peng

James

C.A.

Cullinan

D.R.

Hogg

G.D.

Mudd

J.L.

Zuo

Takchi

Caldwell

K.E.

Liu

DeNardo

D.G.

Fields

R.C.

Gillanders

W.E.

Goedegebuure

S.P.

and Hawkins

W.G.

, Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer, Clinical Cancer Research 27 (2021), 6761–6771.

38.

Zhang

J.-X.

Huang

X.-X.

Cai

M.-B.

Tong

Z.-T.

Chen

J.-W.

Qian

Liao

Y.-J.

Deng

H.-X.

Liao

D.-Z.

Huang

M.-Y.

Zeng

Y.-X.

Xie

and Mai

S.-J.

, Overexpression of the secretory small GTPase Rab27B in human breast cancer correlates closely with lymph node metastasis and predicts poor prognosis, J Transl Med 10 (2012), 242.

39.

Dong

Cui

J.-T.

Yang

W.-M.

Y.-Y.

and Xiao

, Decreased expression of Rab27A and Rab27B correlates with metastasis and poor prognosis in colorectal cancer, Discov Med 20 (2015), 357–367.

40.

Worst

T.S.

Meyer

Gottschalt

Weis

C.-A.

von Hardenberg

Frank

Steidler

Michel

M.S.

and Erben

, RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells, Int J Oncol 50 (2017), 920–932.

41.

Sha

Qin

Chen

Shi

and Feng

, EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells, Oncogene 39 (2020), 2643–2657.

42.

Chen

Huang

A.C.

Zhang

Yang

Wang

Sun

Xia

Man

Zhong

Antelo

L.F.

Xiong

Liu

Guan

Liu

Yang

Dong

McGettigan

Somasundaram

Radhakrishnan

Mills

Kim

Chen

Y.H.

Dong

Zhao

Karakousis

G.C.

Mitchell

T.C.

Schuchter

L.M.

Herlyn

Wherry

E.J.

and Guo

, Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response, Nature 560 (2018), 382–386.

43.

Poggio

Pai

C.-C.

Chu

Belair

C.D.

Chang

Montabana

Lang

U.E.

Fong

and Blelloch

, Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory, Cell 177 (2019), 414–427.e13.

44.

Wolfers

and Lozier

, Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming, Nat Med 38 (2001), 297–303.

45.

Merkow

R.P.

Bilimoria

K.Y.

Tomlinson

J.S.

Paruch

J.L.

Fleming

J.B.

Talamonti

M.S.

C.Y.

and Bentrem

D.J.

, Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer, Ann Surg 260 (2014), 372–377.

46.

Birrer

D.L.

Golcher

Casadei

Haile

S.R.

Fritsch

Hussung

Brunner

T.B.

Fietkau

Meyer

Grützmann

Merkel

Ricci

Ingaldi

di Marco

Guido

Serra

Minni

Pestalozzi

Petrowsky

DeOliveira

Bechstein

W.O.

Bruns

C.J.

Oberkofler

C.E.

Puhan

Lesurtel

Heinrich

and Clavien

P.-A.

, Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials, Ann Surg 274 (2021), 713–720.

RAB27B expression in pancreatic cancer is predictive of poor survival but good response to chemotherapy

Abstract

BACKGROUND:

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Introduction

2. Material and methods

2.1 Patients samples and tissue collection

2.3 Immunohistochemistry evaluation

3. Results

3.1 Patient characteristics

Table 2 Hazard ratios of clinical factors as well as RAB27B expression for overall survival. RAB27B was dichotomized along the median (RAB27B ⩽ 95) and along previously described cutoff values (RAB27B ⩽ 90) [15, 16]

3.3 Correlation of RAB27A and RAB27B expression with overall survival

3.4 Correlation of clinical factors within the subgroups of patients with high or low RAB27A and RAB27B expression

5. Discussion

6. Conclusion

Author contributions

Supplementary data

sj-docx-1-cbm-10.3233_CBM-220460.docx - Supplemental material

Footnotes

Acknowledgments

References

Table 2
Hazard ratios of clinical factors as well as RAB27B expression for overall survival. RAB27B was dichotomized along the median (RAB27B $\leqslant$ 95) and along previously described cutoff values (RAB27B $\leqslant$ 90) [15, 16]